Question-Based Drug Development for Psilocybin – Authors' Reply

The Lancet Psychiatry - United Kingdom
doi 10.1016/s2215-0366(16)30217-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Editorial: Less Acid, Less Cancer? Is This the Question? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Editorial: Refractory GERD-good Drug, Wrong Patients? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Authors’ Reply

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2019English

Authors' Reply

Journal of the American Society of Echocardiography
Nuclear MedicineRadiologyCardiovascular MedicineImagingCardiology
2019English

Authors' Reply:

British Journal of Psychiatry
MedicinePsychiatryMental Health
2010English

Authors' Reply:

British Journal of Psychiatry
MedicinePsychiatryMental Health
2011English

Authors' Reply

British Journal of Psychiatry
MedicinePsychiatryMental Health
2015English

Authors' Reply:

British Journal of Psychiatry
MedicinePsychiatryMental Health
2011English

Authors' Reply

British Journal of Psychiatry
MedicinePsychiatryMental Health
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy